Menu
Menu
Ayahuasca is one of the most popular and least understood of the psychedelic agents. This recording will cover an introduction to ayahuasca, including biochemical, neuroscientific and historical/cultural aspects of its use. Following this, we’ll cover contemporary research on its effects on mental health and its use for treatment of conditions such as addiction and depression. Lastly, some of the psychodynamic aspects of shamanic and syncretic religions settings will be described.
PESI Australia, in collaboration with PESI in the USA, offers quality online continuing professional development events from the leaders in the field at a standard recognized by professional associations including psychology, social work, occupational therapy, alcohol and drug professionals, counselling and psychotherapy. On completion of the training, a Professional Development Certificate is issued after the individual has answered and submitted a quiz and course evaluation. This program is worth 1.25 hours CPD for points calculation by your association.
| File type | File name | Number of pages | |
|---|---|---|---|
| Manual - An Introduction to Ayahuasca for Mental Health Providers (5.51 MB) | 44 Pages | Available after Purchase | |
| Text Document | Transcript (36.2 KB) | 12 Pages | Available after Purchase |
| Manual - An Introduction to Ayahuasca for Mental Health Providers - French (5.2 MB) | 40 Pages | Available after Purchase | |
| Text Document | Transcript - French (36.2 KB) | 12 Pages | Available after Purchase |
| Manual - An Introduction to Ayahuasca for Mental Health Providers - Italian (5.2 MB) | 40 Pages | Available after Purchase | |
| Text Document | Transcript - Italian (36.2 KB) | 12 Pages | Available after Purchase |
Jeffrey Guss, MD, is a psychiatrist, psychoanalyst, researcher and teacher with specializations in psychoanalytic therapy and psychedelic therapy. He is on the faculty of the NYU Postdoctoral Program in Psychotherapy and Psychoanalysis and is a Clinical Assistant Professor of Psychiatry at NYU School of Medicine.
Dr. Guss was the Co-Principal Investigator and Director of Psychedelic Therapy Training for the NYU study on psilocybin-assisted psychotherapy in the treatment of cancer anxiety and is a study therapist with several MAPS studies. He has published on the integration of Acceptance and Commitment Therapy with psychedelic assisted therapy for MDD in Journal of Contextual and Behavioral Science and co-authored a paper on the influence of therapists’’ firsthand psychedelic experiences. He maintains a private practice in New York City.
Speaker Disclosures:
Financial: Dr. Jeffrey Guss is a lead trainer with Fluence. He has employment relationships with California Institute for Integral Studies, Yale University, and Cybin. Dr. Guss maintains a private practice. He receives a speaking honorarium from PESI, Inc.
Non-financial: Dr. Jeffrey Guss is a study therapist with the New York University Medical Center Research and is a sub-investigator in MAPS.
Please wait ...